Published in Cell · View the paper (DOI)
Researchers have discovered a 64-protein signature that can predict which ovarian cancer patients are unlikely to respond to chemotherapy, paving the way for personalized treatment options. The study also identifies five new subtypes of high-grade serous ovarian cancer, suggesting different treatment strategies may be needed.
Coverage from 2 institutions